KVD900 600 mg ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 3 |
65. Primary immunodeficiency
Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05505916 (ClinicalTrials.gov) | October 24, 2022 | 11/8/2022 | An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) | An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II | Hereditary Angioedema | Drug: KVD900 600 mg | KalVista Pharmaceuticals, Ltd. | NULL | Recruiting | 12 Years | N/A | All | 150 | Phase 3 | United States;Australia;Bulgaria;France;Greece;Hungary;Netherlands;Spain;United Kingdom |
| 2 | NCT05511922 (ClinicalTrials.gov) | October 24, 2022 | 11/8/2022 | PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial | A Pharmacokinetic Subtrial in Adolescent Patients With Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial | Hereditary Angioedema | Drug: KVD900 600 mg | KalVista Pharmaceuticals, Ltd. | NULL | Recruiting | 12 Years | 17 Years | All | 12 | Phase 3 | United States;Australia;Bulgaria;France;Greece;Spain;United Kingdom |
| 3 | NCT05259917 (ClinicalTrials.gov) | February 23, 2022 | 4/2/2022 | A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) | A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II | Hereditary Angioedema | Drug: Placebo;Drug: KVD900 600 mg;Drug: KVD900 300 mg | KalVista Pharmaceuticals, Ltd. | NULL | Recruiting | 12 Years | N/A | All | 114 | Phase 3 | United States;Australia;Bulgaria;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;North Macedonia;Poland;Puerto Rico;Romania;Spain;United Kingdom |